Home › Funds › Palo Alto Investors LP › CRSP
Palo Alto Investors LP position in CRSP
CRISPR THERAPEUTICS AG · Health Care
Palo Alto Investors LP reported holding 36,949 shares of CRSP (CRISPR THERAPEUTICS AG) in its Q3 2026 13F filing — a position valued at US$2.0M, representing 0.30% of its reported portfolio and ranking #39 among its reported holdings. Palo Alto Investors LP has disclosed CRSP holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Palo Alto Investors LP's CRSP position evolved
Palo Alto Investors LP first disclosed a stake in CRSP in Q2 2025 at 44,625 shares (US$2.2M). The position peaked in Q3 2025 at 41,226 shares, worth US$2.7M. Across 6 filings, Palo Alto Investors LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 36,949 shares valued at US$2.0M — a reduction of -2,656 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 44.62K | $2.17M | New |
| Q3 2025 | 41.23K | $2.67M | Reduce |
| Q4 2025 | 41.23K | $2.16M | Hold |
| Q1 2026 | 39.60K | $1.88M | Reduce |
| Q2 2026 | 39.60K | $2.16M | Hold |
| Q3 2026 | 36.95K | $2.04M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRSP and 13F data
CRSP (CRISPR THERAPEUTICS AG) is a Health Care company. 29 other funds we track also report a position in CRSP — the largest reported positions include ARK Invest (US$556.3M), Orbis Allan Gray Ltd (US$250.0M), GSK plc (US$144.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRSP
- ARK Invest 10.06M sh · $556.34M · Q3 2026
- Orbis Allan Gray Ltd 4.52M sh · $250.01M · Q3 2026
- GSK plc 2.61M sh · $144.30M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 2.04M sh · $112.78M · Q3 2026
- Amova Asset Management Americas, Inc. 1.45M sh · $80.36M · Q3 2026
- EcoR1 Capital, LLC 1.39M sh · $76.85M · Q3 2026
- NEA Management Company, LLC 1.06M sh · $58.56M · Q3 2026
More on Palo Alto Investors LP
FAQ
How long has Palo Alto Investors LP held CRSP?
Palo Alto Investors LP has disclosed CRSP holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Palo Alto Investors LP's current position in CRSP?
As of Q3 2026, Palo Alto Investors LP holds 36.95K shares of CRSP (CRISPR THERAPEUTICS AG), valued at $2.04M, representing 0.30% of its reported portfolio and ranking #39.
Has Palo Alto Investors LP been buying or selling CRSP?
In the latest 13F filing (Q3 2026), Palo Alto Investors LP reduced its position in CRSP. The position peaked in Q3 2025 at 41.23K shares.
Which other funds hold CRSP?
Other major institutional holders of CRSP include ARK Invest, Orbis Allan Gray Ltd, GSK plc, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.